GlassScriptPhysician profile
Nicholas Kallay
NPI 1043209596
$11,457.74
in general payments reported to CMS, 2019-2025
40 companies · $737 in 2025
The $737 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,555 · 2020: $1,041 · 2021: $1,706 · 2022: $2,281 · 2023: $3,204 · 2024: $934 · 2025: $737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,247 · Travel and Lodging: $496 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,247.29 |
| Travel and Lodging | $495.81 |
| Education | $132.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,525.02 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,245.10 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,194.75 | 2019-2025 | Ofev, Spiriva Respimat, Jascayd |
| Inspire Medical Systems, INC. | $1,098.81 | 2023-2025 | Inspire |
| Genzyme Corporation | $562.94 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $489.81 | 2020-2024 | Glassia |
| Amgen INC. | $482.57 | 2022-2025 | Tezspire |
| Actelion Pharmaceuticals US, INC. | $462.44 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Regeneron Healthcare Solutions, INC. | $460.43 | 2021-2025 | Dupixent |
| Insmed, INC. | $454.02 | 2019-2025 | Arikayce |
| United Therapeutics Corporation | $413.64 | 2019-2024 | Tyvaso |
| Ani Pharmaceuticals, INC. | $243.87 | 2022-2023 | Purified Cortrophin Gel |
| Jazz Pharmaceuticals INC. | $215.27 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $194.28 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $188.10 | 2019-2021 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $182.87 | 2022-2025 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $175.10 | 2019-2025 | Zerbaxa, Recarbrio, Dificid |
| Mylan Specialty L.P. | $167.35 | 2019-2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $160.55 | 2019-2023 | |
| Baxter Healthcare | $150.25 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Mallinckrodt Enterprises LLC | $148.40 | 2019 | |
| Pfizer INC. | $146.30 | 2021-2023 | |
| Genentech USA, INC. | $134.17 | 2019-2022 | |
| Harmony Biosciences LLC | $120.64 | 2020-2023 | Wakix |
| Philips North America LLC | $108.76 | 2019-2021 | |
| Portola Pharmaceuticals, LLC | $89.14 | 2019 | |
| Janssen Pharmaceuticals, INC | $87.96 | 2020-2023 | Xarelto |
| Advanced Respiratory, INC | $78.73 | 2019-2020 | |
| Electromed, INC. | $73.34 | 2019-2025 | Smartvest |
| Gilead Sciences, INC. | $65.88 | 2019-2021 | |
| Avadel Cns Pharmaceuticals, LLC | $49.69 | 2025 | Lumryz |
| Novartis Pharmaceuticals Corporation | $48.13 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $39.77 | 2023 | Nuzyra |
| Idorsia Pharmaceuticals US INC | $35.76 | 2022 | |
| Astellas Pharma US INC | $34.24 | 2023 | Cresemba |
| Alexion Pharmaceuticals, INC. | $33.10 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $31.85 | 2020-2021 | |
| Viatris Specialty LLC | $28.93 | 2025 | Yupelri |
| Lilly USA, LLC | $20.34 | 2025 | Zepbound |
| Circassia INC. | $15.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Kallay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.